Direct estrogen receptor (ER) / HER family crosstalk mediating sensitivity to lumretuzumab and pertuzumab in ER+ breast cancer
Fig 5
Tumor regression in a breast cancer patient treated with lumretuzumab plus pertuzumab and paclitaxel.
This 37-year-old patient received 23 cycles of lumretuzumab and pertuzumab. The black arrow indicates the discontinuation of paclitaxel treatment after 18 weeks. Circles indicate the timing of tumor assessments. Tumors were assessed according to RECIST version 1.1.